[go: up one dir, main page]

DE68924714D1 - Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen. - Google Patents

Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.

Info

Publication number
DE68924714D1
DE68924714D1 DE68924714T DE68924714T DE68924714D1 DE 68924714 D1 DE68924714 D1 DE 68924714D1 DE 68924714 T DE68924714 T DE 68924714T DE 68924714 T DE68924714 T DE 68924714T DE 68924714 D1 DE68924714 D1 DE 68924714D1
Authority
DE
Germany
Prior art keywords
eczemas
medicine
treatment
production
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68924714T
Other languages
English (en)
Other versions
DE68924714T2 (de
Inventor
Anders Frithz
Anders Tollesson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE8800101A external-priority patent/SE460762B/sv
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE68924714D1 publication Critical patent/DE68924714D1/de
Publication of DE68924714T2 publication Critical patent/DE68924714T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C07C57/12—Straight chain carboxylic acids containing eighteen carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
DE68924714T 1988-01-14 1989-06-07 Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen. Expired - Lifetime DE68924714T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8800101A SE460762B (sv) 1988-01-14 1988-01-14 Anvaendning av essentiella fettsyror foer framstaellning av ett preparat foer behandling av infantilt seborroiskt eksem och asteatotiskt eksem
PCT/SE1989/000323 WO1990014824A1 (en) 1988-01-14 1989-06-07 Use of essential fatty acids for the preparation of a drug for the treatment of eczema

Publications (2)

Publication Number Publication Date
DE68924714D1 true DE68924714D1 (de) 1995-12-07
DE68924714T2 DE68924714T2 (de) 1996-05-02

Family

ID=26660089

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68924714T Expired - Lifetime DE68924714T2 (de) 1988-01-14 1989-06-07 Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.

Country Status (5)

Country Link
US (1) US5352700A (de)
EP (1) EP0561766B1 (de)
JP (1) JPH04507397A (de)
DE (1) DE68924714T2 (de)
WO (1) WO1990014824A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4133694C2 (de) * 1991-10-11 1993-10-07 Fresenius Ag Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
DE4238869C2 (de) * 1992-11-18 1994-09-08 Wogepharm Gmbh Mittel zur Behandlung des atopischen Ekzems und anderer entzündlicher Hautkrankheiten
CN1168104A (zh) * 1995-01-18 1997-12-17 大正制药株式会社 皮肤炎治疗剂
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6107334A (en) * 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
US7138431B1 (en) 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
JP2002047176A (ja) * 2000-08-04 2002-02-12 Idemitsu Technofine Co Ltd ＩｇＥ産生抑制剤
WO2002083121A1 (en) * 2001-04-12 2002-10-24 Katsumori Fukumoto Compositions for improving skin environment and clothes thereof
US7763587B2 (en) * 2002-06-13 2010-07-27 L'oreal S.A. Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process
EP1667698B1 (de) 2003-05-22 2009-03-18 Bioniche Life Sciences Inc. Insektenabwehrmittel
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0907413D0 (en) * 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US8673325B1 (en) * 2012-09-06 2014-03-18 Dignity Sciences Limited Cosmetic compositions comprising EPA and salicylic acid and methods of making and using same
EP3068757B1 (de) 2013-11-15 2019-02-27 DS Biopharma Limited Lysinsalz der 15-hydroxy-8(z),11(z),13(e)-eicosatriensäure
EP3151825B1 (de) 2014-06-04 2020-03-25 DS Biopharma Limited Pharmazeutische zusammensetzungen enthaltend dgla und verwendung derselben
HK1250345A1 (zh) 2015-05-13 2018-12-14 Afimmune Limited 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444755A (en) * 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
FR2548021B1 (fr) * 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
GB8326130D0 (en) * 1983-09-29 1983-11-02 Efamol Ltd Topical preparations containing tars and fatty acids
JPS6438007A (en) * 1987-04-28 1989-02-08 Lion Corp Skin external preparation

Also Published As

Publication number Publication date
WO1990014824A1 (en) 1990-12-13
US5352700A (en) 1994-10-04
EP0561766B1 (de) 1995-11-02
EP0561766A1 (de) 1993-09-29
DE68924714T2 (de) 1996-05-02
JPH04507397A (ja) 1992-12-24

Similar Documents

Publication Publication Date Title
DE68924714D1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
DE68911103D1 (de) Verwendung von Fettsäuren zur Behandlung von myalgischer Enzephalomyelitis.
ATE126433T1 (de) Verwendung von gamma-hydroxy-buttersäuresalzen zur herstellung von pharmazeutischen zusammensetzungen zur verwendung bei der behandlung von alkoholismus und die hergestellten zusammensetzungen.
DE3484055D1 (de) Verwendung von ubidecarenon zur herstellung eines medikaments zur behandlung von durch radiotherapie hervorgerufenen geschwueren.
DE3585607D1 (de) Verwendung von paroxetine zur herstellung eines arzneimittel zur behandlung von obesitaet.
DE68924619D1 (de) Stereolithographisches Verfahren zur Herstellung von Prothesen.
DE3785740D1 (de) Verwendung von carboxamid-verbindungen zur herstellung eines arzneimittels zur behandlung der hyperlipaemie.
DE3583220D1 (de) Verwendung von dipeptidderivaten fuer die herstellung von arzneimitteln zur behandlung von an amyotropher lateralsklerose erkrankten.
DE68918207D1 (de) Verfahren zur Herstellung von Levodopa.
DE69637449D1 (de) Verwendung von alpha-hydroxysäuren zur herstellung eines arzneimittels für die behandlung von entzündungen
DE69318909D1 (de) Verfahren zur Herstellung von menschlichem Wachstumshormon
DE58906613D1 (de) Verfahren zur Herstellung von orthodontischen Teilen.
DE68922042D1 (de) Verfahren zur Herstellung von Titanoxid.
DE3784518D1 (de) Medizinisches material und verfahren zur herstellung.
DE58901037D1 (de) Vorrichtung zur herstellung von klareisstuecken.
DE69125489D1 (de) Verwendung von derivaten durch menschliches gallensalz stimulierter lipase zur herstellung von medikamenten
DE3851364D1 (de) Verfahren zur Herstellung von supraleitendem Material.
DE3766619D1 (de) Verwendung von dicarbonsaeuren mit 7-13 kohlenstoffatomen oder physiologisch vertraeglichen salzen davon zur herstellung eines arzneimittels zur topischen behandlung von rosazea.
DE3675115D1 (de) Verwendung von verbindungen zur herstellung eines medikaments fuer die behandlung von grauem star.
DE68916760D1 (de) Verfahren zur Herstellung von Gamma-Lactonen.
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
DE68920087D1 (de) Verfahren zur Herstellung von Neuraminidase.
DE3578374D1 (de) Verwendung von chinolonen fuer die herstellung eines arzneimittels zur behandlung von herzerkrankungen.
DE58905133D1 (de) Verwendung eines goldbades zur herstellung von zahnersatz.
DE3873210D1 (de) Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition